Immunotherapy

The Society for Immunotherapy of Cancer created the Steven A. Rosenberg, MD, PhD, Endowed Scholars Fund.

A personalized cancer vaccine improved PFS compared with historical outcomes with standard-of-care treatment for patients with newly diagnosed glioblastoma, according to phase 2 study results.

Letetresgene autoleucel demonstrated clinical activity among patients with advanced synovial sarcoma, according to final phase 1 study results presented at the virtual Society for Immunotherapy of Cancer Annual Meeting.

Letetresgene autoleucel demonstrated clinical activity among patients with advanced synovial sarcoma, according to final phase 1 study results presented at the virtual Society for Immunotherapy of Cancer Annual Meeting.

Nearly half of oncology clinicians reported being unfamiliar with emerging immunotherapies, according to survey results presented at the virtual Society for Immunotherapy of Cancer’s Annual Meeting.

Continued nivolumab treatment after 1 year appeared effective and safe for certain patients with advanced non-small cell lung cancer, according to an exploratory analysis of the CheckMate 153 study published in Journal of Clinical Oncology.

In this video, Roy S. Herbst, MD, PhD, associate cancer center director for translational research at Yale Cancer Center, highlighted updated data in squamous cell lung cancer and mesothelioma presented at the Chemotherapy Foundation Symposium.

In this video, Roy S. Herbst, MD, PhD, associate cancer center director for translational research at Yale Cancer Center, discussed this year’s Chemotherapy Foundation Symposium.

Chimeric antigen receptor T-cell therapies are the apex of a practice-changing shift in the treatment of acute lymphoblastic leukemia, according to a presenter at NCCN 2020 Virtual Congress: Hematologic Malignancies.

The immune cells of young and female individuals typically are very potent due to genetic and hormonal factors.